Abstract：Objective: To explore the correlation between the level of serum human cartilage glycoprotein 39 (YKL-40), epidermal growth factor (EGF), amyloid A (SAA) and cognitive impairment of patients with Parkinson's disease (PD). Methods: A total of 62 PD patients admitted to our hospital from May 2019 to May 2020 were selected as the observation group, and 60 healthy controls during the same period for physical examination were selected as the control group. Analyze the serum YKL-40, EGF, and SAA levels of the observation group and the control group, the Montreal Cognitive Assessment Scale (MoCA) score, and record the observation group’s Parkinson’s disease unified score scale (UPDRS) score. Pearson was used to analyze the correlation between UPDRS score, MoCA score and serum YKL-40, EGF, SAA levels in PD patients. Results: The serum YKL-40, EGF and SAA levels of the observation group were significantly higher than those of the control group, and the MoCA score was significantly lower than that of the control group. There was a statistical difference between the two groups (P<0.05). The condition of patients in the observation group was recorded, including UPDRS Ⅰ (3.84 ± 0.47) points, UPDRS Ⅱ (23.83 ± 3.07) points, and UPDRS Ⅲ (29.9 ± 3.49) points. Pearson was used to analyze the correlation between UPDRS score, MoCA score and serum YKL-40, EGF, SAA levels in PD patients, and the results showed that serum YKL-40、EGF, SAA levels were negatively correlated with MoCA score (r = -0.425, -0.548,- 0.455, P<0.01), and UPDRSⅠ (r=0.604, 0.645, 0.592, P<0.01), UPDRSⅡ (r=0.559, 0.527, 0.636, P<0.01), UPDRSⅢ (r=0.584, 0.709, 0.613, P<0.01) 0.01). The scores were positively correlated. Conclusion: The levels of serum YKL-40, EGF and SAA in PD patients are significantly increased, and are closely related to the patient's condition and cognitive impairment. The index levels have certain reference value for clinical early detection and treatment.
孙妮, 时晶, 刘贵安. 血清EGF YKL-40 SAA水平与帕金森病患者认知障碍的相关性分析[J]. 河北医学, 2021, 27(7): 1090-1093.
SUN Ni, SHI Jing, LIU Gui'an. Correlation Analysis of Serum EGF YKL-40 SAA Levels and Cognitive Impairment of Patients with Parkinson's Disease. HeBei Med, 2021, 27(7): 1090-1093.
[1] 马芸,徐海清,钱展,等.MMSE正常的帕金森病患者定量脑电图与早期认知障碍的相关性[J].中国神经免疫学和神经病学杂志,2018,25(1):57~61. [2] Akiyama H,Nukui S,Akamatu M,et al.Effectiveness of spinal cord stimulation for painful camptocormia with pisa syndrome in parkinson's disease: a case report[J].Bmc Neurology,2017,17(1):148. [3] Singh P,Hanson P S,Morris C M.SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in parkinson's disease[J].Bmc Neuroence,2017,18(1):46. [4] 成昕毅,刘军.滋肝养肾复脉汤联合多巴丝肼对帕金森病患者的影响[J].西部中医药,2019,32(12):77~79. [5] 潘晓峰,刘文娟.普拉克索联合行为疗法对早发帕金森病合并抑郁患者HAMD UPDRS评分非运动症状及生活质量的影响[J].河北医学,2019,25(8):1240~1243. [6] Kinghorn K J,Asghari A M,Jorge Ivan Castillo-Quan.The emerging role of autophagic-lysosomal dysfunction in gaucher disease and Parkinson's disease[J].Neural Regeneration Research,2017,12(3):380~384. [7] 彭珊,杨飞,张树山,等.帕金森病非运动症状研究进展[J].中国临床神经科学,2017,25(5):567~572,594. [8] 吴文波,王超,牛德旺,等.血清Aβ1-42、UA水平和血清炎症因子与帕金森病发病的相关性研究[J].中国实验诊断学,2018,22(3):484~486. [9] 冯阳,唐自强,杨莉.血清YKL-40,RANTES,SSA水平和帕金森病患者Mo CA评分的关系[J].卒中与神经疾病,2019,26(5):595~598. [10] 谢勇.血清表皮生长因子水平与帕金森病患者认知障碍的关系研究[J].实用心脑肺血管病杂志,2017,25(8):49~52.
2021, Vol. 27 
冀公网安备13080202000677号